{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T04:10:28Z","timestamp":1733371828746,"version":"3.30.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,4]]},"DOI":"10.7759\/cureus.75120","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T03:28:02Z","timestamp":1733369282000},"source":"Crossref","is-referenced-by-count":0,"title":["Liver Enzymes and Inflammatory Markers Among Severely Ill COVID-19 Patients: A Retrospective Case-Control Study in Telangana"],"prefix":"10.7759","author":[{"given":"Pratyusha","family":"Pavuluri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M Girija","family":"Menon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarat Chandan","family":"Tummalacharla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaik","family":"Sameer Raheem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soujanya","family":"Karpay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phanindra","family":"Chepuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.9540","article-title":"Effect of COVID-19 on the organs","volume":"12","author":"Jain U","year":"2020","unstructured":"Jain U. Effect of COVID-19 on the organs. Cureus. 2020, 12:e9540. 10.7759\/cureus.9540","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106054","article-title":"Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies","volume":"56","author":"Sharma A","year":"2020","unstructured":"Sharma A, Tiwari S, Deb MK, Marty JL. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. Int J Antimicrob Agents. 2020, 56:106054. 10.1016\/j.ijantimicag.2020.106054","journal-title":"Int J Antimicrob Agents"},{"key":"ref3","article-title":"Features, evaluation, and treatment of coronavirus (COVID-19)","author":"Cascella M","year":"2024","unstructured":"Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref4","unstructured":"Worldometer. COVID-19 coronavirus pandemic. (2024). Accessed: September 30, 2024: https:\/\/www.worldometers.info\/coronavirus\/."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_1570_21","article-title":"Multi-organ system involvement in coronavirus disease 2019 (COVID-19): a mega review","volume":"11","author":"Moslehi N","year":"2022","unstructured":"Moslehi N, Jahromy MH, Ashrafi P, et al.. Multi-organ system involvement in coronavirus disease 2019 (COVID-19): a mega review. J Family Med Prim Care. 2022, 11:5014-23. 10.4103\/jfmpc.jfmpc_1570_21","journal-title":"J Family Med Prim Care"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-020-04138-6","article-title":"COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection","volume":"40","author":"Beyerstedt S","year":"2021","unstructured":"Beyerstedt S, Casaro EB, Rangel \u00c9B. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis. 2021, 40:905-19. 10.1007\/s10096-020-04138-6","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref7","article-title":"A review on laboratory liver function tests","volume":"3","author":"Gowda S","year":"2009","unstructured":"Gowda S, Desai PB, Hull VV, Math AA, Vernekar SN, Kulkarni SS.  A review on laboratory liver function tests. Pan Afr Med J. 2009, 3:17.","journal-title":"Pan Afr Med J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112419","article-title":"Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications","volume":"145","author":"Majidpoor J","year":"2022","unstructured":"Majidpoor J, Mortezaee K. Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications. Biomed Pharmacother. 2022, 145:112419. 10.1016\/j.biopha.2021.112419","journal-title":"Biomed Pharmacother"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26097","article-title":"Elevated level of C\u2010reactive protein may be an early marker to predict risk for severity of COVID\u201019","volume":"92","author":"Ali N","year":"2020","unstructured":"Ali N. Elevated level of C\u2010reactive protein may be an early marker to predict risk for severity of COVID\u201019. J Med Virol. 2020, 92:2409-11. 10.1002\/jmv.26097","journal-title":"J Med Virol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0256744","article-title":"D-dimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19","volume":"16","author":"Poudel A","year":"2021","unstructured":"Poudel A, Poudel Y, Adhikari A, et al.. D-dimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19. PLoS One. 2021, 16:e0256744. 10.1371\/journal.pone.0256744","journal-title":"PLoS One"},{"key":"ref11","article-title":"Tiez textbook of clinical chemistry, ed 2","year":"1994","unstructured":"Tiez textbook of clinical chemistry, ed 2. Burtis C, Ashwood E (ed). WB Saunders, Philadelphia; 1994."},{"key":"ref12","article-title":"CLSI EP05-A2 | evaluation of precision performance of quantitative measurement methods; approved guideline - second edition","year":"2004","unstructured":"CLSI EP05-A2 | evaluation of precision performance of quantitative measurement methods; approved guideline - second edition. Clinical and Laboratory Standards Institute, 2004."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1515\/CCLM.2001.179","article-title":"The existing interim consensus reference ranges and the future approach","volume":"39","author":"Dati F","year":"2001","unstructured":"Dati F, Johnson AM, Whicher JT. The existing interim consensus reference ranges and the future approach. Clin Chem Lab Med. 2001, 39:1134-6. 10.1515\/CCLM.2001.179","journal-title":"Clin Chem Lab Med"},{"key":"ref14","article-title":"Liver injury in COVID- 19: management and challenges","volume":"5","author":"Shi L","year":"2020","unstructured":"Shi L, Wang F. Liver injury in COVID- 19: management and challenges. Lancet Gastroenterol Hepatol. 2020, 5:428-30.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.36349","article-title":"The spectrum of COVID-19-induced liver injury in various age and risk groups","volume":"15","author":"Bhusal T","year":"2023","unstructured":"Bhusal T, Banjade P, Surani S, Sharma M. The spectrum of COVID-19-induced liver injury in various age and risk groups. Cureus. 2023, 15:e36349. 10.7759\/cureus.36349","journal-title":"Cureus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2020.00126","article-title":"Progress in the clinical features and pathogenesis of abnormal liver enzymes in coronavirus disease 2019","volume":"9","author":"Wu H","year":"2021","unstructured":"Wu H, Liu S, Luo H, Chen M. Progress in the clinical features and pathogenesis of abnormal liver enzymes in coronavirus disease 2019. J Clin Transl Hepatol. 2021, 9:239-46. 10.14218\/JCTH.2020.00126","journal-title":"J Clin Transl Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s13738-020-02049-z","article-title":"The ACE2 as a \u201crescue protein\u201d or \u201csuspect enzyme\u201d in COVID-19: possible application of the \u201cengineered inactive hrsACE2\u201d as a safer therapeutic agent in the treatment of SARS-CoV-2 infection","volume":"18","author":"Khodarahmi R","year":"2020","unstructured":"Khodarahmi R, Sayad B, Sobhani M. The ACE2 as a \u201crescue protein\u201d or \u201csuspect enzyme\u201d in COVID-19: possible application of the \u201cengineered inactive hrsACE2\u201d as a safer therapeutic agent in the treatment of SARS-CoV-2 infection. 2020, 18:495-502. 10.1007\/s13738-020-02049-z"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.31031\/MADD.2021.03.000568","article-title":"The Tibetan Medicine Rhodiola is Effective Against Inflammatory Storms. Modern Approaches in Drug Designing. 3","volume":"3","author":"Li W","year":"2054","unstructured":"Li W. The Tibetan Medicine Rhodiola is Effective Against Inflammatory Storms. Modern Approaches in Drug Designing. 3. Mod App Drug Design. 2054, 3:10.31031\/MADD.2021.03.000568","journal-title":"Mod App Drug Design"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-020-01301-7","article-title":"Overview of COVID-19 inflammatory pathogenesis from the therapeutic perspective","volume":"44","author":"Lee C","year":"2021","unstructured":"Lee C, Choi WJ. Overview of COVID-19 inflammatory pathogenesis from the therapeutic perspective. Arch Pharm Res. 2021, 44:99-116. 10.1007\/s12272-020-01301-7","journal-title":"Arch Pharm Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival","volume":"26","author":"Del Valle DM","year":"2020","unstructured":"Del Valle DM, Kim-Schulze S, Huang HH, et al.. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020, 26:1636-43. 10.1038\/s41591-020-1051-9","journal-title":"Nat Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102537","article-title":"The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease","volume":"19","author":"McGonagle D","year":"2020","unstructured":"McGonagle D, Sharif K, O'Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020, 19:102537. 10.1016\/j.autrev.2020.102537","journal-title":"Autoimmun Rev"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2020-0369","article-title":"Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis","volume":"58","author":"Henry BM","year":"2020","unstructured":"Henry BM, de Oliveira MH, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020, 58:1021-8. 10.1515\/cclm-2020-0369","journal-title":"Clin Chem Lab Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-73939-9","article-title":"The specific metabolome profiling of patients infected by SARS-COV-2 supports the key role of tryptophan-nicotinamide pathway and cytosine metabolism","volume":"10","author":"Blasco H","year":"2020","unstructured":"Blasco H, Bessy C, Plantier L, et al.. The specific metabolome profiling of patients infected by SARS-COV-2 supports the key role of tryptophan-nicotinamide pathway and cytosine metabolism. Sci Rep. 2020, 10:16824. 10.1038\/s41598-020-73939-9","journal-title":"Sci Rep"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2174\/1389450123666220826162900","article-title":"Fibrinogen, fibrin, and fibrin degradation products in COVID-19","volume":"23","author":"Kangro K","year":"2022","unstructured":"Kangro K, Wolberg AS, Flick MJ. Fibrinogen, fibrin, and fibrin degradation products in COVID-19. Curr Drug Targets. 2022, 23:1593-602. 10.2174\/1389450123666220826162900","journal-title":"Curr Drug Targets"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.06.029","article-title":"The hypercoagulable state in COVID-19: incidence, pathophysiology, and management","volume":"194","author":"Abou-Ismail MY","year":"2020","unstructured":"Abou-Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L. The hypercoagulable state in COVID-19: incidence, pathophysiology, and management. Thromb Res. 2020, 194:101-15. 10.1016\/j.thromres.2020.06.029","journal-title":"Thromb Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1684\/ecn.2020.0448","article-title":"Interleukin-6 and severe COVID-19: a systematic review and meta-analysis","volume":"31","author":"Mojtabavi H","year":"2020","unstructured":"Mojtabavi H, Saghazadeh A, Rezaei N. Interleukin-6 and severe COVID-19: a systematic review and meta-analysis. Eur Cytokine Netw. 2020, 31:44-9. 10.1684\/ecn.2020.0448","journal-title":"Eur Cytokine Netw"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa1103","article-title":"C-reactive protein and clinical outcomes in patients with COVID-19","volume":"42","author":"Smilowitz NR","year":"2021","unstructured":"Smilowitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, Berger JS. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021, 42:2270-9. 10.1093\/eurheartj\/ehaa1103","journal-title":"Eur Heart J"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31404","article-title":"Acute liver injury in COVID- 19: prevalence and association with clinical outcomes in a large U.S. cohort","volume":"72","author":"Phipps MM","year":"2020","unstructured":"Phipps MM, Barraza LH, LaSota ED, et al.. Acute liver injury in COVID- 19: prevalence and association with clinical outcomes in a large U.S. cohort. Hepatology. 2020, 72:807-17. 10.1002\/hep.31404","journal-title":"Hepatology"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang C","year":"2020","unstructured":"Huang C, Wang Y, Li X, et al.. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020, 395:497-506. 10.1016\/S0140-6736(20)30183-5","journal-title":"Lancet"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.19607","article-title":"Deranged liver function tests and liver insults in malnourished patients: a report of two cases and literature review","volume":"13","author":"Pinheiro J","year":"2021","unstructured":"Pinheiro J, Jameel I, Palejwala A. Deranged liver function tests and liver insults in malnourished patients: a report of two cases and literature review. Cureus. 2021, 13:e19607. 10.7759\/cureus.19607","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/313084-liver-enzymes-and-inflammatory-markers-among-severely-ill-covid-19-patients-a-retrospective-case-control-study-in-telangana","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T03:28:08Z","timestamp":1733369288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/313084-liver-enzymes-and-inflammatory-markers-among-severely-ill-covid-19-patients-a-retrospective-case-control-study-in-telangana"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.75120","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,4]]}}}